Peregrine Capital Management LLC Sells 244,443 Shares of Ocular Therapeutix, Inc. $OCUL

Peregrine Capital Management LLC lessened its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 28.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 617,519 shares of the biopharmaceutical company’s stock after selling 244,443 shares during the quarter. Peregrine Capital Management LLC owned about 0.35% of Ocular Therapeutix worth $7,219,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Nisa Investment Advisors LLC grew its position in shares of Ocular Therapeutix by 62.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,392 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Ocular Therapeutix by 17.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 893 shares during the last quarter. Trust Co. of Vermont boosted its stake in Ocular Therapeutix by 16.1% during the 2nd quarter. Trust Co. of Vermont now owns 7,200 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 1,000 shares during the period. Marex Group plc acquired a new stake in Ocular Therapeutix in the 2nd quarter valued at approximately $115,000. Finally, Rafferty Asset Management LLC grew its holdings in Ocular Therapeutix by 21.2% in the 2nd quarter. Rafferty Asset Management LLC now owns 13,413 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 2,343 shares during the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix Stock Down 1.1%

Shares of OCUL stock opened at $11.26 on Friday. Ocular Therapeutix, Inc. has a one year low of $5.78 and a one year high of $16.44. The company has a debt-to-equity ratio of 0.27, a current ratio of 7.85 and a quick ratio of 7.78. The stock has a fifty day moving average price of $12.32 and a 200 day moving average price of $11.92. The stock has a market cap of $2.40 billion, a P/E ratio of -7.82 and a beta of 0.93.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.02. The company had revenue of $14.54 million during the quarter, compared to analysts’ expectations of $14.57 million. Ocular Therapeutix had a negative net margin of 447.57% and a negative return on equity of 86.33%. Analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Chardan Capital reiterated a “buy” rating and set a $21.00 price target on shares of Ocular Therapeutix in a report on Tuesday, December 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Wednesday, October 8th. Zacks Research upgraded shares of Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 2nd. Needham & Company LLC restated a “buy” rating and issued a $20.00 price target on shares of Ocular Therapeutix in a research report on Monday, December 8th. Finally, HC Wainwright boosted their price objective on shares of Ocular Therapeutix from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $22.56.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.